Delivery Order SPE2DR25D3504-SPE2DR26F7BM7
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of CAPLYTA 42 mg capsules (30-count packages) with a ceiling value of $1,297.13. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The order is scheduled for completion by December 9, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $1,278.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units). AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was selected through competitive procurement with no set-aside designation. The delivery order has an ultimate completion date of July 23, 2025, with performance at the contractor's Conshohocken...
- The Defense Logistics Agency awarded a $6,535.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units). The contract, which is not set-aside, is scheduled for completion by November 19, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,868.18 to supply CAPLYTA 42 mg capsules (30-count units) under a firm fixed-price contract. The order was competitively awarded without set-aside designation and is scheduled for completion by December 11, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, fulfilled this order from its corporate office location, leveraging its established role as a critical pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $7,064.84 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 21 mg capsules (30-count units) under a firm fixed price contract. The award was made on November 25, 2025, with an ultimate completion date of November 26, 2025, and represents a non-competitive set-aside transaction. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this delivery order from its...
- The Defense Logistics Agency awarded a delivery order valued at $9,468.39 to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of CAPLYTA 21 mg capsules (30-count units). This competitively awarded, firm fixed-price contract represents a non-set-aside delivery order with an ultimate completion date of September 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order contract valued at $36,356.83 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units). This was a competitively awarded, firm fixed-price delivery order with no set-aside designation, issued on November 17, 2025, with an ultimate completion date of November 18, 2025. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-unit packages) with a ceiling value of $2,971.27 under firm fixed pricing. The award, issued on November 7, 2025, with an ultimate completion date of November 10, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate...
- The Defense Logistics Agency awarded a $2,088.32 delivery order to AmerisourceBergen Drug Corp for CAPLYTA 21 mg capsules (30-count package) on November 24, 2025, with completion expected by November 25, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical will be delivered to the company's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on September 16, 2025, for the supply of CAPLYTA 42 mg capsules in a quantity of 30 units. This firm fixed price delivery order, valued at $29,358.50 with an ultimate completion date of September 17, 2025, represents a non-set-aside competitive award. The contract will be performed at the awardee's corporate office location in...
- SPE2DR25D3504Indefinite Delivery Contract
- SPE2DR25D3504-SPE2DR26F7BM7Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of CAPLYTA 42 mg capsules (30-count packages) with a contract value of $7,397.74. This competitively awarded, firm fixed-price delivery order is scheduled for completion by December 9, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's demonstrated capability to compete in open federal procurement processes. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive portfolio of medications and medical supplies to support military and veteran healthcare systems. The company's extensive contract history with DLA demonstrates its role as a key provider of specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains to the Defense Health Agency and other government healthcare organizations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.4k | 12/7/25 |